AXSM
Axsome Therapeutics, Inc.
Overview
Axsome Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $12.87B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 2, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0421 Q&A exchanges
- Q4 FY2025Earnings2026-02-2319 Q&A exchanges
- Q3 FY2025Earnings2025-11-0320 Q&A exchanges
- Q2 FY2025Earnings2025-08-0422 Q&A exchanges
- Q1 FY2025Earnings2025-05-0525 Q&A exchanges
- Q4 FY2024Earnings2025-02-1827 Q&A exchanges
- Q3 FY2024Earnings2024-11-1236 Q&A exchanges
- Q2 FY2024Earnings2024-08-0522 Q&A exchanges
- Q1 FY2024Earnings2024-05-0623 Q&A exchanges
- Q4 FY2023Earnings2024-02-2031 Q&A exchanges
- Q3 FY2023Earnings2023-11-0634 Q&A exchanges
- Q2 FY2023Earnings2023-08-0734 Q&A exchanges
- Q1 FY2023Earnings2023-05-0829 Q&A exchanges
- Q4 FY2022Earnings2023-02-2734 Q&A exchanges
- Q3 FY2022Earnings2022-11-0725 Q&A exchanges
- Q2 FY2022Earnings2022-08-0928 Q&A exchanges
- Q1 FY2022Earnings2022-05-0249 Q&A exchanges
- Q4 FY2021Earnings2022-03-0146 Q&A exchanges
- Q3 FY2021Earnings2021-11-0843 Q&A exchanges
- Q2 FY2021Earnings2021-08-0947 Q&A exchanges
- Q1 FY2021Earnings2021-05-1038 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-02EPS— vs $-0.82—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-02 | — | $-0.82 | — | — | — | — | EODHD |
Source: EODHD. AXSM reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks AXSM's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.70 | $1.86 | +45.4% | +2.1% | +1.4% |
| Q4 FY2026 | $2.55 | $1.79 | +42.6% | +6.8% | +7.9% |
| Q3 FY2026 | $2.62 | $1.90 | +37.9% | -4.3% | -6.0% |
| Q2 FY2026 | $2.77 | $1.93 | +43.5% | +6.2% | +8.2% |
| Q1 FY2025 | $2.71 | $1.85 | +46.7% | -2.6% | -2.3% |
| Q4 FY2025 | $2.61 | $1.90 | +37.3% | +1.8% | +1.7% |
| Q3 FY2025 | $2.72 | $1.91 | +42.3% | +4.3% | +2.9% |
| Q2 FY2025 | $2.56 | $1.87 | +37.0% | +0.8% | +2.5% |
| Q1 FY2024 | $3.01 | $2.10 | +43.2% | -2.6% | -0.3% |
| Q4 FY2024 | $2.80 | $2.00 | +40.2% | -2.3% | -4.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Herriot TabuteauCEO9 mo21 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance cut Q3 FY2026
- Nick PizzieCFO5 mo21 callsCurrentSample
CFO since 2026 • 2/2 beats (100%) • last guidance cut Q2 FY2026
- Mark L JacobsonCOO1 yr19 callsCurrentSample
COO since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
- Ari MaizelChief Commercial Officer5 mo10 callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance raise Q1 FY2026
- Hunter R MurdockGeneral Counsel1 yr5 callsCurrentSample
OTHER since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AXSM.
$ curl https://api.spokenalpha.com/v1/companies/AXSMFAQ
Frequently asked about AXSM
Where can I find Axsome Therapeutics, Inc.'s (AXSM) earnings call transcripts?
Spoken Alpha indexes AXSM's earnings call transcripts at https://spokenalpha.com/companies/AXSM. Each call links to attributed speakers and parsed analyst Q&A.
When was Axsome Therapeutics, Inc.'s most recent earnings call?
Axsome Therapeutics, Inc. (AXSM) held its most recent earnings call on 2026-05-04, covering fiscal Q1 2026.
What sector is AXSM in?
Axsome Therapeutics, Inc. (AXSM) operates in the Healthcare sector (Biotechnology industry).